ClinicalTrials.gg
Status unknownNCT04683757Updated Dec 24, 2020

The Establishment of a Survival Prediction Model for ER Positive / HER-2 Negative Advanced Breast Cancer

An observational study in Breast Cancer, sponsored by Ying Wang. Status unknown at 2 sites in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-12-24.

Sponsored by Ying Wang · Observational

How we know

The sponsor has not verified this record recently (last verified Dec 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
288
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,936 studies in Breast Neoplasms with a site in China — 871 open to participants now, 1,068 under way, 211 of them phase 3. Breast Neoplasms · China.

Planned enrollment
194th of 409
288 · median 240
Started
2020
with 127 others
Observational
409 of 1,936
176 open now
Registered
704th of 1,936
by date

Among the 1,936 studies in Breast Neoplasms with a site in China, this one is the 194th largest by planned enrollment of the 409 observational ones that give a count, is one of 128 that started in 2020, is one of 409 observational ones, and was the 704th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

871 of the 1,936 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

866 more — sign in →

All 871 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,936 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

This project is a prospective, clinical cohort study initiated by researchers to study the high-risk factors affecting the overall survival of newly diagnosed ER + / HER2 - advanced breast cancer patients and to establish a prediction model of ER + / HER2 - advanced breast cancer patients affecting overall survival. This project is the first prospective prediction model for the survival of patients with advanced breast cancer, and it is also the first time to establish a survival prediction model for ER-positive / HER2 negative advanced breast cancer suitable for China's national conditions. According to the survival outcome predicted by the model, the newly diagnosed ER positive / HER2 negative advanced breast cancer was divided into three groups: low, medium, and high risk, which provided an important theoretical basis for further design of randomized controlled clinical research and guidance of individualized precise treatment scheme for different groups in the future.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
  • a Survival Prediction Model
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

breast cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At the time of signing the form, 18 years old ≤ 70 years old, female
  2. ER positive breast cancer confirmed by pathology: ER positive (≥ 1%) by immunohistochemistry
  3. Newly diagnosed advanced patients, including patients with early breast cancer who have evidence of recurrence and after therapy and patients with stage IV breast cancer at the first visit
  4. Patients who are willing to receive follow-up treatment in the research center.

Exclusion criteria

Exclusion Criteria:

  1. ErbB-2 gene amplification was recorded by fish (defined as / CEP17 ratio ≥ 2) or chromogenic in situ hybridization (CISH) or IHC (defined as ihc3 +, or ihc2 + confirmed by fish or CISH) was used to record HER2 positive tumors.
  2. Any form of anti-cancer treatment has been carried out for recurrent or lesions
  3. Combined with other malignant tumors or had other malignant tumors in recent 5 years
  4. Patients with nervous system disorders caused by diseases or obvious mental disorders will affect patients' right to know, compliance or make them in a dangerous state
  5. Patients with less than 3 months
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
288 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • OtherEstablishment of a Survival Prediction Model

    a nomogram to predict the survival of patients with ER positive / HER-2 negative advanced breast cancer

06

What researchers measure

Primary outcomes

  1. overall survival,OS

    The time from the beginning of treatment to the death of the patient

    Time frame: 5 years

  2. Tumor specific survival time, CSS

    The follow-up started from the first day of confirmed recurrence and metastasis. The end point of follow-up was the death caused by tumor related causes.

    Time frame: 5 years

Secondary outcomes

  1. Progression Free Survival,PFS

    The time from the beginning of treatment to the progression or death of the patient.

    Time frame: 2 years

  2. 5-year survival rate

    the survival rate in 5 years

    Time frame: 5 years

07

Study locations

1 of 2 sites recruiting
  • Sun Yat Sen Memorial Hospital,Sun Yat sen University
    Guangzhou, Guangdong 510000, China
    Completed
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guanzhou, Guangdong 510000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2020 (actual). Primary completion is estimated for Jan 2021, 12 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 12 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2020
First posted
Dec 24, 2020
StartActual
Jan 1, 2020
Primary completionEst.
Jan 1, 2021
CompletionEst.
Dec 31, 2024
Last update
Dec 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04683757
Lead sponsor
Ying Wang
Responsible party
Ying Wang (Professor, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University) — Sponsor-investigator
First posted
Dec 24, 2020
Start date
Jan 1, 2020
Primary completion
Jan 1, 2021 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Dec 24, 2020

Study contacts

Ying Dr. Wang, doctor
Contact
wangy556@mail.sysu.edu.cn
86-20-34070499
Jianli Zhao
Contact
zhaojli5@mail.sysu.edu.cn
86-20-34070870

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion